炎症性贫血的病因、诊断与治疗研究进展  

Anemia of Inflammation in the Etiology Diagnosis and Treatment Research Progress

作　　者：丁琪[1] 孙涛[1] 马丹丹[1] 邹德勇[1] 王峥辉[1] 郭晓今[1] 蒲晓彦 杨丽云[3] 

机构地区：[1]武警总医院检验科,北京100039 [2]武警特警学院门诊部,北京102211 [3]武警总医院军人科,北京100039

出　　处：《现代生物医学进展》2014年第21期4196-4200,共5页Progress in Modern Biomedicine

摘　　要：感染、自身免疫紊乱、慢性疾病和年龄等很多原因都会导致炎症发生并发展为贫血。炎症性贫血(anemia of inflammation AI)通常为正细胞正色素性贫血,临床表现温和。系统性的铁利用、红细胞生成、红细胞生存期特征的变化导致了炎症性贫血。最佳治疗是纠正病因,然而当病因不清或难以诊断时,治疗炎症性贫血的办法就非常有限了。铁调素(Hepcidin)是近年研究铁利用调节的中心。由于铁调素定量分析技术的发展,人们逐渐认识到其在各种疾病中的作用。最近研究集中在铁调素表达调节通路,并发现了药物治疗的靶点。由于治疗上的巨大进步,分析正常血红蛋白对疾病预后的影响,就可以明确炎性疾病发生和死亡过程中贫血是否具有可逆性。Inflammation arises from various etiologies, including autoimmune disorders, chronic diseases, aging and many other complications, and can easily develop into anemia. The anemia of inflammation （AI） is most often normocytic and normochromic and is usually mild. Characteristic changes in systemic iron handling, erythrocyte production and erythrocyte life span all contribute to AI. The preferred treatment is directed the underlying disease, however, when the etiology is not clear or difficult to diagnose, there are limited ptions for treatment. The role of heOcidin was also studied and revealed as the technology for quanttative analysis improves. Recent insight concerning the regulatory pathways that modify hepcidin expression have identified novel targets for drug development. Due to the great advances in treatment, the analysis of normalized hemoglobin on disease outcomes will confirm whether anemia is a reversible contributor to the morbidity and mortality associated with inflammatory diseases.

关 键 词：炎性贫血 病因 诊断 治疗 

分 类 号：R556[医药卫生—血液循环系统疾病]